Anna Roppelt

MD, Doctor of Immunology Department
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
of the Ministry of Healthcare of Russian Federation, Moscow, Russian Federation
GENERAL INFORMATION
Anna Roppelt
Roppelt Anna, MD is currently a doctor in the Immunology Department and Research Associate in Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology.
Dr.Roppelt graduated from Lomonosov Moscow State University, Faculty of Fundamental Medicine in 2013 and completed residency in Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, speciality — Allergy and immunology.
The focus of Research interests of Dr. Roppelt is X-linked lymphoproliferative syndromes. In 2018 Dr.Roppelt carried out a research project "Gene therapy and gene editing as a potential therapeutic approach for patients with XIAP-deficiency" on the basis of UCL Great Ormond Street Institute of Child Health(London).
Hematopoietic Stem Cell Transplantation
as a Curative Option of Monogenic
Forms
of Inflammatory Bowel Disease

Sharing the Experience at International Conference in Moscow, Russia, November 2019
Inflammatory bowel diseases (IBD), that include Crohn's disease and ulcerative colitis, - are long lasting diseases, progressing under the influence of a wide range of factors: genetic and environmental. For the moment, there come up more and more monogenic forms of IBD, in which one defected gene changes the whole clinical pattern. The monogenic forms of IBD manifest usually very early, in the childhood. A major part of these types of diseases deal with primary immunodeficiency. Primary immune deficiency diseases (PIDD) - are a group of genetic diseases, caused by the defects of the genes, responsible for immunologic response. Allogenic transplantation of hematopoietic stem cells (AHSCT) is a treatment option for a large amount of PIDD and for the treatment of complications. The review of PIDD that usually cause inflammation in the bowel, will be presented the results of treatment of this group of diseases with allogenic HSCT will be demonstrated.

References:
Anna Roppelt
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of the Healthcare of Russian Federation, Moscow, Russian Federation